Combination immunotherapy with radiation and CpG-based tumor vaccination for the eradication of radio- and immuno-resistant lung carcinoma cells

Kenji Chamoto, Tsuguhide Takeshima, Daiko Wakita, Takayuki Ohkuri, Shigeru Ashino, Tokuhiko Omatsu, Hiroki Shirato, Hidemitsu Kitamura, Yuji Togashi, Takashi Nishimura

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Unmethylated cytosine-phosphorothioate-guanine containing oligodeoxynucleotides (CpG-ODN) is known as a ligand of toll-like receptor 9 (TLR9), which selectively activates type-1 immunity. We have already reported that the vaccination of tumor-bearing mice with liposome-CpG coencapsulated with model-tumor antigen, ovalbumin (OVA) (CpG + OVA-liposome) caused complete cure of the mice bearing OVA-expressing EG-7 lymphoma cells. However, the same therapy was not effective to eradicate Lewis lung carcinoma (LLC)-OVA-carcinoma. To overcome the refractoriness of LLC-OVA, we tried the combination therapy of radiation with CpG-based tumor vaccination. When LLC-OVA-carcinoma intradermally (i.d.) injected into C57BL/6 became palpable (7-8 mm), the mice were irradiated twice with a dose of 14 Gy at intervals of 24 h. After the second radiation, CpG + OVA-liposome was i.d. administered near the draining lymph node (DLN) of the tumor mass. The tumor growth of mice treated with radiation plus CpG + OVA-liposome was greatly inhibited and approximately 60% of mice treated were completely cured. Moreover, the combined therapy with radiation and CpG+ OVA-liposome allowed the augmented induction of OVA-tetramer + LLC-OVA-specific cytotoxic T lymphocyte (CTL) in DLN of tumor-bearing mice. These results indicate that the combined therapy of radiation with CpG-based tumor vaccine is a useful strategy to eradicate intractable carcinoma.

Original languageEnglish (US)
Pages (from-to)934-939
Number of pages6
JournalCancer Science
Volume100
Issue number5
DOIs
StatePublished - 2009

Fingerprint

Ovalbumin
Radio
Immunotherapy
Vaccination
Radiation
Carcinoma
Lung
Lewis Lung Carcinoma
Liposomes
Neoplasms
Radiotherapy
Lymph Nodes
Toll-Like Receptor 9
Cancer Vaccines
Oligodeoxyribonucleotides
Cytosine
Guanine
Cytotoxic T-Lymphocytes
Neoplasm Antigens
Immunity

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Combination immunotherapy with radiation and CpG-based tumor vaccination for the eradication of radio- and immuno-resistant lung carcinoma cells. / Chamoto, Kenji; Takeshima, Tsuguhide; Wakita, Daiko; Ohkuri, Takayuki; Ashino, Shigeru; Omatsu, Tokuhiko; Shirato, Hiroki; Kitamura, Hidemitsu; Togashi, Yuji; Nishimura, Takashi.

In: Cancer Science, Vol. 100, No. 5, 2009, p. 934-939.

Research output: Contribution to journalArticle

Chamoto, K, Takeshima, T, Wakita, D, Ohkuri, T, Ashino, S, Omatsu, T, Shirato, H, Kitamura, H, Togashi, Y & Nishimura, T 2009, 'Combination immunotherapy with radiation and CpG-based tumor vaccination for the eradication of radio- and immuno-resistant lung carcinoma cells', Cancer Science, vol. 100, no. 5, pp. 934-939. https://doi.org/10.1111/j.1349-7006.2009.01114.x
Chamoto, Kenji ; Takeshima, Tsuguhide ; Wakita, Daiko ; Ohkuri, Takayuki ; Ashino, Shigeru ; Omatsu, Tokuhiko ; Shirato, Hiroki ; Kitamura, Hidemitsu ; Togashi, Yuji ; Nishimura, Takashi. / Combination immunotherapy with radiation and CpG-based tumor vaccination for the eradication of radio- and immuno-resistant lung carcinoma cells. In: Cancer Science. 2009 ; Vol. 100, No. 5. pp. 934-939.
@article{b9cff60d6c3b43399d30ff27ce9f339f,
title = "Combination immunotherapy with radiation and CpG-based tumor vaccination for the eradication of radio- and immuno-resistant lung carcinoma cells",
abstract = "Unmethylated cytosine-phosphorothioate-guanine containing oligodeoxynucleotides (CpG-ODN) is known as a ligand of toll-like receptor 9 (TLR9), which selectively activates type-1 immunity. We have already reported that the vaccination of tumor-bearing mice with liposome-CpG coencapsulated with model-tumor antigen, ovalbumin (OVA) (CpG + OVA-liposome) caused complete cure of the mice bearing OVA-expressing EG-7 lymphoma cells. However, the same therapy was not effective to eradicate Lewis lung carcinoma (LLC)-OVA-carcinoma. To overcome the refractoriness of LLC-OVA, we tried the combination therapy of radiation with CpG-based tumor vaccination. When LLC-OVA-carcinoma intradermally (i.d.) injected into C57BL/6 became palpable (7-8 mm), the mice were irradiated twice with a dose of 14 Gy at intervals of 24 h. After the second radiation, CpG + OVA-liposome was i.d. administered near the draining lymph node (DLN) of the tumor mass. The tumor growth of mice treated with radiation plus CpG + OVA-liposome was greatly inhibited and approximately 60{\%} of mice treated were completely cured. Moreover, the combined therapy with radiation and CpG+ OVA-liposome allowed the augmented induction of OVA-tetramer + LLC-OVA-specific cytotoxic T lymphocyte (CTL) in DLN of tumor-bearing mice. These results indicate that the combined therapy of radiation with CpG-based tumor vaccine is a useful strategy to eradicate intractable carcinoma.",
author = "Kenji Chamoto and Tsuguhide Takeshima and Daiko Wakita and Takayuki Ohkuri and Shigeru Ashino and Tokuhiko Omatsu and Hiroki Shirato and Hidemitsu Kitamura and Yuji Togashi and Takashi Nishimura",
year = "2009",
doi = "10.1111/j.1349-7006.2009.01114.x",
language = "English (US)",
volume = "100",
pages = "934--939",
journal = "Cancer Science",
issn = "1347-9032",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - Combination immunotherapy with radiation and CpG-based tumor vaccination for the eradication of radio- and immuno-resistant lung carcinoma cells

AU - Chamoto, Kenji

AU - Takeshima, Tsuguhide

AU - Wakita, Daiko

AU - Ohkuri, Takayuki

AU - Ashino, Shigeru

AU - Omatsu, Tokuhiko

AU - Shirato, Hiroki

AU - Kitamura, Hidemitsu

AU - Togashi, Yuji

AU - Nishimura, Takashi

PY - 2009

Y1 - 2009

N2 - Unmethylated cytosine-phosphorothioate-guanine containing oligodeoxynucleotides (CpG-ODN) is known as a ligand of toll-like receptor 9 (TLR9), which selectively activates type-1 immunity. We have already reported that the vaccination of tumor-bearing mice with liposome-CpG coencapsulated with model-tumor antigen, ovalbumin (OVA) (CpG + OVA-liposome) caused complete cure of the mice bearing OVA-expressing EG-7 lymphoma cells. However, the same therapy was not effective to eradicate Lewis lung carcinoma (LLC)-OVA-carcinoma. To overcome the refractoriness of LLC-OVA, we tried the combination therapy of radiation with CpG-based tumor vaccination. When LLC-OVA-carcinoma intradermally (i.d.) injected into C57BL/6 became palpable (7-8 mm), the mice were irradiated twice with a dose of 14 Gy at intervals of 24 h. After the second radiation, CpG + OVA-liposome was i.d. administered near the draining lymph node (DLN) of the tumor mass. The tumor growth of mice treated with radiation plus CpG + OVA-liposome was greatly inhibited and approximately 60% of mice treated were completely cured. Moreover, the combined therapy with radiation and CpG+ OVA-liposome allowed the augmented induction of OVA-tetramer + LLC-OVA-specific cytotoxic T lymphocyte (CTL) in DLN of tumor-bearing mice. These results indicate that the combined therapy of radiation with CpG-based tumor vaccine is a useful strategy to eradicate intractable carcinoma.

AB - Unmethylated cytosine-phosphorothioate-guanine containing oligodeoxynucleotides (CpG-ODN) is known as a ligand of toll-like receptor 9 (TLR9), which selectively activates type-1 immunity. We have already reported that the vaccination of tumor-bearing mice with liposome-CpG coencapsulated with model-tumor antigen, ovalbumin (OVA) (CpG + OVA-liposome) caused complete cure of the mice bearing OVA-expressing EG-7 lymphoma cells. However, the same therapy was not effective to eradicate Lewis lung carcinoma (LLC)-OVA-carcinoma. To overcome the refractoriness of LLC-OVA, we tried the combination therapy of radiation with CpG-based tumor vaccination. When LLC-OVA-carcinoma intradermally (i.d.) injected into C57BL/6 became palpable (7-8 mm), the mice were irradiated twice with a dose of 14 Gy at intervals of 24 h. After the second radiation, CpG + OVA-liposome was i.d. administered near the draining lymph node (DLN) of the tumor mass. The tumor growth of mice treated with radiation plus CpG + OVA-liposome was greatly inhibited and approximately 60% of mice treated were completely cured. Moreover, the combined therapy with radiation and CpG+ OVA-liposome allowed the augmented induction of OVA-tetramer + LLC-OVA-specific cytotoxic T lymphocyte (CTL) in DLN of tumor-bearing mice. These results indicate that the combined therapy of radiation with CpG-based tumor vaccine is a useful strategy to eradicate intractable carcinoma.

UR - http://www.scopus.com/inward/record.url?scp=65349097349&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=65349097349&partnerID=8YFLogxK

U2 - 10.1111/j.1349-7006.2009.01114.x

DO - 10.1111/j.1349-7006.2009.01114.x

M3 - Article

C2 - 19245434

AN - SCOPUS:65349097349

VL - 100

SP - 934

EP - 939

JO - Cancer Science

JF - Cancer Science

SN - 1347-9032

IS - 5

ER -